AstraZeneca outlined a $15 billion investment program for China through 2030, announcing capital deployment across manufacturing, R&D and partnership activity to expand local capabilities. Company statements and BioCentury reporting indicate the plan pairs direct investment with minority venture stakes and multiple licensing deals to accelerate access to Chinese innovation and scale AstraZeneca’s cell‑therapy and radioconjugate efforts. Analysts and company executives framed the move as a strategic hedge against competitive momentum in China and a pathway to faster global development of China‑origin assets. The strategy emphasizes venture partnerships and deal flow as tools to source novel modalities while building in‑country capacity to support later‑stage global programs, reflecting a two‑pronged approach to capture both innovation and manufacturing scale.